IN BRIEF: Scancell hurt by revaluation of derivative liability loss
30th Jan 2025 19:54
Scancell Holdings PLC - Oxford, UK-based pharmaceutical firm - Pretax loss multiplies to GBP13.8 million in the six months to October 31 from GBP3.6 million a year prior. R&D expenses rise to GBP8.0 million from GBP5.7 million, administrative expenses edge up to GBP2.5 million from GBP2.4 million. Bottom line hit by GBP4.5 million loss relating to revaluation of derivative liability compared to GBP4.9 million gain a year prior. Cash balances at October 31 are GBP9.1 million compared to GBP14.8 million at April 30, 2024. Sees cash runway to the second half of 2026 beyond multiple clinical milestones. Read More